Israel Fernandez-Pineda1, Andrew M Davidoff1, Lu Lu2, Bhaskar N Rao1, Carmen L Wilson2, D Kumar Srivastava3, James L Klosky4, Monica L Metzger5, Matthew J Krasin6, Kirsten K Ness2, Ching-Hon Pui5, Leslie L Robison2, Melissa M Hudson2,6, Charles A Sklar7, Daniel M Green2, Wassim Chemaitilly2,8. 1. Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tenness. 2. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 7. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, New York. 8. Department of Pediatric Medicine, Division of Endocrinology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: We reviewed the effect of ovarian transposition (OT) on ovarian function among long-term survivors of childhood Hodgkin lymphoma (HL) treated with pelvic radiotherapy. PROCEDURE: Female participants (age 18+ years) with HL in the St. Jude Lifetime Cohort Study (SJLIFE) were clinically evaluated for premature ovarian insufficiency (POI) 10 or more years after pelvic radiotherapy. Reproductive history including age at menopause and pregnancy/live births was available on all patients. RESULTS: Of 127 eligible females with HL, 90 (80%) participated in SJLIFE, including 49 who underwent OT before pelvic radiotherapy. Median age at STLIFE evaluation was 38 years (range 25-60). In a multiple regression adjusted for age at diagnosis, pelvic radiotherapy doses > 1,500 cGy (hazard ratio [HR] = 25.2, 95% confidence interval [CI] = 3.1-207.3; P = 0.0027) and cumulative cyclophosphamide equivalent doses of alkylating agents > 12,000 mg/m2 (HR = 11.2, 95% CI = 3.4-36.8; P < 0.0001) were significantly associated with POI. There was no significant association between OT and occurrence of POI (HR = 0.6, 95% CI = 0.2-1.9; P = 0.41). CONCLUSIONS: OT did not appear to modify risk of POI in this historic cohort of long-term survivors of HL treated with gonadotoxic therapy. Modern fertility preservation modalities, such as mature oocyte cryopreservation, should be offered to at-risk patients whenever feasible.
BACKGROUND: We reviewed the effect of ovarian transposition (OT) on ovarian function among long-term survivors of childhood Hodgkin lymphoma (HL) treated with pelvic radiotherapy. PROCEDURE: Female participants (age 18+ years) with HL in the St. Jude Lifetime Cohort Study (SJLIFE) were clinically evaluated for premature ovarian insufficiency (POI) 10 or more years after pelvic radiotherapy. Reproductive history including age at menopause and pregnancy/live births was available on all patients. RESULTS: Of 127 eligible females with HL, 90 (80%) participated in SJLIFE, including 49 who underwent OT before pelvic radiotherapy. Median age at STLIFE evaluation was 38 years (range 25-60). In a multiple regression adjusted for age at diagnosis, pelvic radiotherapy doses > 1,500 cGy (hazard ratio [HR] = 25.2, 95% confidence interval [CI] = 3.1-207.3; P = 0.0027) and cumulative cyclophosphamide equivalent doses of alkylating agents > 12,000 mg/m2 (HR = 11.2, 95% CI = 3.4-36.8; P < 0.0001) were significantly associated with POI. There was no significant association between OT and occurrence of POI (HR = 0.6, 95% CI = 0.2-1.9; P = 0.41). CONCLUSIONS: OT did not appear to modify risk of POI in this historic cohort of long-term survivors of HL treated with gonadotoxic therapy. Modern fertility preservation modalities, such as mature oocyte cryopreservation, should be offered to at-risk patients whenever feasible.
Authors: Wassim Chemaitilly; Zhenghong Li; Matthew J Krasin; Russell J Brooke; Carmen L Wilson; Daniel M Green; James L Klosky; Nicole Barnes; Karen L Clark; Jonathan B Farr; Israel Fernandez-Pineda; Michael W Bishop; Monika Metzger; Ching-Hon Pui; Sue C Kaste; Kirsten K Ness; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Yutaka Yasui; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2017-07-01 Impact factor: 5.958
Authors: Robert D van Beek; Marry M van den Heuvel-Eibrink; Joop S E Laven; Frank H de Jong; Axel P N Themmen; Friederike G Hakvoort-Cammel; Cor van den Bos; Henk van den Berg; Rob Pieters; Sabine M P F de Muinck Keizer-Schrama Journal: J Clin Endocrinol Metab Date: 2007-08-28 Impact factor: 5.958
Authors: Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2013-08-12 Impact factor: 3.167
Authors: Wassim Chemaitilly; Ann C Mertens; Pauline Mitby; John Whitton; Marilyn Stovall; Yutaka Yasui; Leslie L Robison; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2006-02-21 Impact factor: 6.134
Authors: Johannes Rosenbrock; Andrés Vásquez-Torres; Horst Mueller; Karolin Behringer; Matthias Zerth; Eren Celik; Jiaqi Fan; Maike Trommer; Philipp Linde; Michael Fuchs; Peter Borchmann; Andreas Engert; Simone Marnitz; Christian Baues Journal: Front Oncol Date: 2021-05-25 Impact factor: 6.244